title: Agomelatine in unipolar depression in clinical practice: a retrospective chart review.
abstract: Agomelatine (Valdoxan), a synthetic melatonergic receptor agonist at the MT1 and MT2 receptors, was first used in the management of sleep disorder. Its 5HT2C receptor antagonistic properties support its antidepressant potential. It is currently licensed in the UK, Europe and USA for the treatment of major depressive disorder. Although the randomized controlled evidence base for its use is growing, there are no retrospective, naturalistic studies available. We aimed to determine the tolerability and clinical effectiveness of agomelatine in unipolar depression. We also examined whether being refractory to treatment altered clinical outcome. Forty-eight patient records were examined. Twenty-five percent were treatment refractory: Clinical Global Impression (CGI) Severity score at the start of treatment was 3.81 compared with 3.38 at the end of treatment. Fifty-four percent improved at least minimally; only 12.5% were much or very much improved. Treatment-refractory patients had a poorer outcome with higher discontinuation rates and lower CGI Improvement (p = 0.0205). Treatment-refractory patients also had a higher CGI Severity score at the end of treatment than at treatment commencement (3.92 versus 3.75), although this was not statistically significant.
authors: Julie
authors: J
authors: Langan
authors: Polash
authors: P
authors: Shajahan
authors: Daniel
authors: D
authors: Martin
authors: Rebecca
authors: R
authors: Carleton
keywords: agomelatine; depression; polypharmacy; retrospective
references: Psychopharmacology (Berl). 2007 Mar;190(4):575-9
references: 17171557
references: J Clin Psychiatry. 2004 Jul;65(7):975-81
references: 15291687
references: J Clin Psychiatry. 2010 Feb;71(2):109-20
references: 20193645
references: Arch Gen Psychiatry. 2010 Jan;67(1):26-36
references: 20048220
references: Biol Psychiatry. 1997 Feb 15;41(4):406-18
references: 9034535
references: Psychopharmacology (Berl). 2002 May;161(2):143-51
references: 11981594
references: Arch Gen Psychiatry. 1992 Aug;49(8):651-68; discussion 669-70
references: 1386215
references: J Clin Psychopharmacol. 2008 Oct;28(5):561-6
references: 18794654
references: Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S31-5
references: 16436938
references: Bipolar Disord. 2007 Sep;9(6):628-35
references: 17845278
references: Can J Psychiatry. 2007 Jan;52(1):46-54
references: 17444078
references: J Clin Psychiatry. 2007 Nov;68(11):1723-32
references: 18052566
references: J Clin Psychiatry. 2010 May;71(5):616-26
references: 20361916
references: Br J Psychiatry. 2002 Oct;181:284-94
references: 12356654
references: Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73
references: 17477888
references: Int Clin Psychopharmacol. 2010 Nov;25(6):305-14
references: 20856123
references: Br J Psychiatry. 1998 Oct;173:325-9
references: 9926037
references: J Clin Psychiatry. 2003;64 Suppl 2:14-8
references: 12625794
references: CNS Drugs. 2009;23 Suppl 2:41-7
references: 19708725
references: Sleep Med. 2007 Dec;9(1):33-41
references: 17826314
references: Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S21-4
references: 16436936
references: J Clin Psychiatry. 2003 May;64(5):568-74
references: 12755661
references: J Psychiatr Pract. 2005 Jul;11(4):241-7
references: 16041234
references: J Clin Psychiatry. 2009 Aug;70(8):1128-37
references: 19689920
references: J Psychopharmacol. 2008 Sep;22(7):778-83
references: 18308790
references: Psychiatry (Edgmont). 2007 Jul;4(7):28-37
references: 20526405
references: Harv Rev Psychiatry. 2005 Sep-Oct;13(5):257-71
references: 16251165
references: Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6
references: 17477886
references: Br J Psychiatry. 2005 May;186:410-6
references: 15863746
references: Int J Neuropsychopharmacol. 2002 Sep;5(3):217-28
references: 12366874